Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
“I am excited to welcome Sung to the leadership team and believe that his exceptional track record of improving operational performance, leading large teams, and communicating with investors, as well as his deep experience and success in financial planning and analysis, will have a significant impact on Sangamo as we continue to grow,” said Sandy Macrae, Sangamo's Chief Executive Officer.
Mr. Lee joins Sangamo from Gilead Sciences, where he spent nearly 14 years, most recently as Senior Vice President leading the financial planning & analysis (FP&A) and investor relations functions. In this dual capacity, he managed the global planning and budgeting process, drove process improvement, and managed all aspects of communications to the investor community. Prior to this role, Mr. Lee held roles of increasing responsibility at Gilead, including Head of Europe Finance and Head of R&D FP&A.
Mr. Lee received a B.A. in Economics from University of California, Irvine, and a M.B.T. from University of Southern California.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com
This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's anticipated growth as a clinical stage development company and into commercialization. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual and Quarterly Reports as filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
Source: Sangamo Therapeutics, Inc.